Teladoc Health raised its 2026 outlook after better-than-expected third-quarter results, as BetterHelp’s insurance pivot gained traction and Integrated Care profitability…
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or…
